News Article | May 4, 2017
Dr. Nyirady is a board certified dermatologist with over 18 years of pharmaceutical experience in all aspects of clinical research and development. She also has medical affairs expertise within both systemic and topical drugs. Prior to joining LEO, Dr. Nyirady worked at Novartis, most recently as interim Medical Unit Head of Dermatology & Immunology, U.S. Clinical Development & Medical Affairs and concurrently as the Executive Director, Dermatology, U.S. Clinical Development & Medical Affairs. Before joining Novartis in 2003, Dr. Nyirady worked at Johnson & Johnson Consumer Products Worldwide (CPWW) as Director of Medical Affairs, Dermatology. Dr. Nyirady holds a M.B.A. from Cornell University, Johnson Graduate School of Management and obtained her medical degree in Hungary from Albert Szent-Györgyi Medical University. About LEO Pharma in the United States LEO Pharma Inc. is a subsidiary of LEO Pharma A/S ("LEO Pharma"), serving the United States, helping people suffering from skin diseases with treatments for psoriasis, actinic keratosis and atopic dermatitis. It is based in Madison, NJ. LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 4,800 people worldwide. More information can be found at www.leo-pharma.us To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/leo-pharma-us-welcomes-judit-h-nyirady-as-vice-president-of-medical-strategy--scientific-affairs-300451629.html
Cazzaniga S.,Centro Studi GISED |
Gentile C.,Medical Unit |
Iannazzone S.S.,G Rummo Hospital |
Cusano F.,G Rummo Hospital |
Naldi L.,Centro Studi GISED
Giornale Italiano di Dermatologia e Venereologia | Year: 2012
Aim. A negative impact on vitiligo patients in terms of quality of life (QoL) has been suggested. The aim of this report was to study the QoL in a sample of Italian vitiligo patients by using the Dermatology Life Quality Index (DLQI) questionnaire. Methods. A sample of forty seven vitiligo subjects, identified among 34,740 potential conscripts resident in southern Italy underwent the Italian version of the DLQI questionnaire. Results. The median total DLQI score was 1 (IQR: 2; mean: 1.82). In univariate analysis, DLQI total score was significantly influenced by the clinical course of vitiligo, disease extension over the body, and location on face and/or hands. Multivariate analysis using logistic stepwise regression showed that only the localization on the hands and on the face influenced significantly the mean DLQI. Conclusion. Our study conducted on a random sample of individuals affected by vitiligo selected from the general young male population in Italy, does not document a large impact of vitiligo on QoL. However, variations exist and the location of lesions on the face and/or hands may impact on QoL. Population-based studies are not affected by selection biases connected with seeking medical care and should be more widely performed.
Afolabi M.O.S.,Duquesne University |
Afolabi M.O.S.,Medical Unit
African Journal of Science, Technology, Innovation and Development | Year: 2013
Non-availability of affordable medicines remains a recurring theme in the healthcare sector of countries in the South where it hampers drug compliance and creates an ambience for continued morbidity and mortality. Countries in sub-Saharan Africa have attempted to remedy this situation via developing drugs from indigenous pharmacopeia; however, their efforts have yielded only a collection of one-off success stories due to a prevailing climate of economic, infrastructural and technological constraints. Using Nigeria as a case example, this paper argues that the core issues plaguing pharmaceutical innovation in developing countries go beyond existing constraints but revolve around an inability to evolve viable frameworks vis-à-vis scientific validation as well as failure on the part of researchers (in the course of conducting their research) and policy makers (in formulating and implementing drug-related policies) to reckon with the local reality. On this note, this paper explores a disruptive innovational framework (DIM) for stimulating extant and novel drug development based on phytomedicinal epistemic currents. Ultimately, this would be helpful in distinguishing the good from the ugly, extricating the rational from the bulk of the irrational, preserving the useful and discarding the completely useless amidst indigenous medicinal knowledge. © 2013 Taylor & Francis.
News Article | February 15, 2017
MORRISVILLE, N.C. & CLEVELAND--(BUSINESS WIRE)--VIGILINT and Cleveland Clinic are collaborating to offer the Global MedAssist Program (GMAP), a telemedicine program available at anytime from anywhere in the world. This collaboration combines VIGILINT's highly specialized emergency physicians and emergency preparedness experts with Cleveland Clinic’s global practice of physicians and specialists. GMAP provides 24/7/365 medical assistance for travelers worldwide. Created in response to the increased demand for high-level medical care and consultations for global travelers, the distance health collaboration augments existing health insurance with on-demand, full-spectrum care through a single point of contact. “We are excited to join forces with world-renowned healthcare leader Cleveland Clinic to offer the global business community a robust telemedicine solution,” said James Humphlett, VIGILINT Chief Executive Officer. Dr. Sean Siler, VIGILINT’s President and Chief Medical Officer, added, “GMAP is unrivaled in the marketplace, with unparalleled reach and most significantly has an unmatched global network of medical providers and facilities.” “Combining the expertise and capabilities of both organizations provides access and proper guidance on medical issues that may arise to those traveling internationally,” said Jonathan Schaffer, MD, MBA, FACS, Managing Director, Cleveland Clinic Distance Health My Consult. “As a leader in telemedicine and distance health initiatives, GMAP has been developed to remove the geographic barriers to care, anywhere, anytime. We are delighted to be a part of this collaboration.” The foundation of GMAP is its 24/7/365 medical operations center, integrating innovative technology and advanced telemedicine intelligence with highly trained operations analysts and proprietary data sources. One call to the Medical Operations Center and the seamless network of care begins. No matter the scale of the healthcare issue or location of the patient, GMAP ensures immediate access to viable and reputable healthcare providers who deliver comprehensive individualized healthcare solutions and continuity of care throughout the medical ordeal. The GMAP team includes VIGILINT physicians that have previous experience with the military, National Security Council, the Centers for Disease Control and Prevention, the White House Medical Unit, and the U.S. Departments of Homeland Security and Health & Human Services, combined with Cleveland Clinic’s more than 3,000 physicians practicing in 140 medical specialties and subspecialties. GMAP was created with a multinational workforce in mind and designed to mitigate the realities of international travel. One in three travelers will experience a medical issue while abroad, one in 30 will need to seek emergency medical care, and 17 percent of travelers admitted to hospitals require aeromedical transfer. Jet lag, stress, limited preparation time, and increased prevalence of chronic and lifestyle-associated diseases make business travelers far more vulnerable to disease than the general population. Local healthcare providers, hospitals, and pharmacies may lack the adequate resources, training, experience, or patient records for proper treatment of business travelers with chronic or emergency health problems. To learn more about the GMAP suite of medical services call: 1-800-970-0395 or visit http://www.vigilint.com/gmap-global-medical-assistance-program/. About Cleveland Clinic Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Among Cleveland Clinic’s 49,000 employees are more than 3,400 full-time salaried physicians and researchers and 14,000 nurses, representing 140 medical specialties and subspecialties. The Cleveland Clinic health system includes a 165-acre main campus near downtown Cleveland, nine community hospitals, more than 150 northern Ohio outpatient locations – including 18 full-service family health centers and three health and wellness centers – and locations in Weston, Fla.; Las Vegas, Nev.; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2015, there were 6.6 million outpatient visits, 164,700 hospital admissions and 208,807 surgical cases throughout the Cleveland Clinic health system. Patients came for treatment from every state and 180 countries. Visit us at www.clevelandclinic.org. Follow us at www.twitter.com/ClevelandClinic. About VIGILINT Founded in 2006, VIGILINT is a medical and travel risk management company that provides health protection for global workforces including corporate medical advisory, 24/7/365 telemedicine, crisis management and expeditionary services to multinational corporations, government clients and individuals. www.VIGILINT.com
Mahillo B.,Medical Unit |
Carmona M.,World Health Organization |
Alvarez M.,Technical Unit |
White S.,George Institute for Global Health |
And 2 more authors.
Transplantation | Year: 2011
The Global Observatory on Donation and Transplantation represents the most comprehensive source of worldwide data concerning activities in organ donation and transplantation and information on legal and organizational aspects. Of the countries reporting information, 84.7% have a national structure supervising or coordinating donation and transplantation and 91% have specific legislation. Worldwide approximately 104,065 solid organ transplants are performed each year. There is a vast difference in rates of kidney and liver transplantation, especially from deceased donor depending on the level of development. This analysis provides an overview of existing organizational structures, related legislation, and activities. © 2011 Lippincott Williams & Wilkins.
News Article | February 15, 2017
Jim DeMaioribus Named VP of Marketing; Christopher Cano Named VP, Business Development; Stephane Levy, MD Named VP of Research & Development U.S. Operations EXTON, PA--(Marketwired - February 14, 2017) - Almirall's Aqua Pharmaceuticals, a specialty dermatology company focusing on acquiring, developing and marketing prescription medical dermatology products in the U.S., has today announced it has hired three key executives. Jim DeMaioribus has been appointed Vice President of Marketing and Christopher Cano has been named Vice President, Business Development, both reporting to Ted White, President & General Manager at Aqua Pharmaceuticals. Stephane Levy, MD will fill the role of Vice President of Research & Development U.S. Operations, reporting to Thomas Eichholtz, Head of Research & Development at Almirall. "Jim, Christopher and Stephane have played an integral role in advancing the pharmaceutical industry in their respective disciplines," said White. "Their proven leadership skills and deep expertise makes them ideally suited to help Aqua Pharmaceuticals build its product portfolio in the U.S." In this role, DeMaioribus will be responsible for developing and implementing marketing strategies and tactics that strengthen the Aqua brand, and help drive profitable growth across the portfolio of Aqua products. Prior to joining Aqua Pharmaceuticals, DeMaioribus was Founder and Managing Director of LSM Marketing, LLC which advised some of the top life science companies on marketing strategies designed to accelerate growth. Before forming LSM Marketing, Jim spent 13 years with Johnson & Johnson where he held a variety of senior marketing and commercial positions across its pharmaceutical and medical device businesses. He currently serves as a Fellow at the Wharton School of the University of Pennsylvania. As Vice President of Business Development, Cano will lead all U.S. business development projects. He will work cross-functionally with the Almirall Global Business Development team, establishing strong relationships with key opinion leaders in order to assess new markets and pursue relevant dermatology opportunities. Cano has a high level of expertise in key therapeutic areas such as dermatology, diabetes care and women's health. Prior to joining Aqua Pharmaceuticals, Cano worked at Duchesnay as Director of Business Development, at Noven Pharmaceuticals as Associate Director of Business Development, and held roles of increasing responsibilities at Nucryst Pharmaceuticals and Barrier Therapeutics. In Dr. Levy's new role, he will be responsible for the leadership and management of Aqua Pharmaceuticals' U.S. Research and Product Development organization including all aspects of project management, clinical development, chemistry, manufacturing & controls, toxicology, regulatory affairs, medical affairs and quality assurance. Overseeing the development of all new drug and device products for the U.S. market, he will lead a team to develop, implement and coordinate product lifecycle infrastructure, ensuring the consistent manufacturing of safe and effective products. Before joining Aqua Pharmaceuticals, Dr. Levy served as Vice President and Medical Unit Head of Immunology & Dermatology at Novartis U.S. Throughout his more than 20 years of experience in in clinical development, he has also held executive roles at Genzyme and Sanofi. Headquartered in West Chester, Pennsylvania, Aqua Pharmaceuticals, an Almirall company, is dedicated to helping patients achieve their goals of healthy skin and a positive self-image. The company has leading branded prescription drugs in four therapeutic categories that include acne, steroid-responsive dermatoses, actinic keratoses and seborrheic dermatitis. For more information, please visit www.aquapharm.com. Almirall is a global company based in Barcelona dedicated to providing valuable medicines and medical devices through its R&D, agreements and alliances. Our work covers the whole of the drug value chain. A consolidated growth allows us to devote our talent and efforts towards specialty areas and particularly to further grow as a leading Dermatology player. We are a specialist company, enabling us to accomplish the purpose of providing our innovative products wherever they are needed. Founded in 1943, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision, and the commitment of its long-standing major shareholders. In 2015, Almirall revenues totalled 769 million euros and, with 1,800 employees, it has become a trusted presence across Europe, as well as in the U.S. For more information, please visit www.almirall.com.
Rubio G.,University Hospital 12 Of Octubre |
Rubio G.,Hospital Universitario La Paz |
Bobes J.,University of Oviedo |
Cervera G.,Unidad University |
And 4 more authors.
European Addiction Research | Year: 2011
Aim: To evaluate the effectiveness of pregabalin as a tapering therapy on the subjective sleep quality of patients who underwent a benzodiazepine withdrawal program in routine medical practice. Methods: Secondary analysis of a 12-week prospective, open noncontrolled study carried out in patients who met DSM-IV-TR criteria for benzodiazepine dependence. Sleep was evaluated with the Medical Outcomes Study Sleep Scale (MOS Sleep Scale). Results: 282 patients were included in the analysis. Mean (±SD) pregabalin dose was 315 ± 166 mg/day at the end of the trial. We observed a significant and clinically relevant improvement in sleep outcomes at the endpoint, with a total score reduction from 55.8 ± 18.9 to 25.1 ± 18.0 at week 12 (i.e. a 55% reduction). Similar findings were apparent using the six dimensions of the MOS Sleep Scale. Moderate correlations were observed between the MOS Sleep summary index and sleep domains, and there were improvements in anxiety symptoms and disease severity. Conclusions: These findings suggest that pregabalin may improve subjective sleep quality in patients who underwent a benzodiazepine withdrawal program. This effect appears to be partly independent of improvements in symptoms of anxiety or withdrawal. However, controlled studies are needed to establish the magnitude of the effect of pregabalin. Copyright © 2011 S. Karger AG, Basel.
Maki M.H.,Medical Unit |
Maki M.H.,University of Baghdad
Journal of Craniofacial Surgery | Year: 2010
In Iraq, oral and maxillofacial (OMF) infections are common; these infections may be of odontogenic or nonodontogenic origin. The former, the commoner, gains importance from the catastrophic consequences that may take place in neglected or mismanaged patients and, as a paradox, from a fact that most of these infections are avoidable and preventable if a timely and accurate management took place for the primary dental problem. Nonodontogenic infections are not uncommon and are of life-threatening potential. Most of these infections are associated with an underlying medical condition that, whenever controlled, can help achieve acceptable results. Although missile injuries-associated infections are almost exclusively of bacterial origin, a separated section is assigned in this article for these infections, in addition to other varieties of bacterial, viral, and fungal infections.The article gives an account of common presentations, diagnostic procedures, treatment protocols, and outcomes of management of OMF infections in Baghdad's central OMF surgery department. These infections are considered as one of the elementary problems in OMF clinics; thus, highlighting significant points extirpated from an overall view of a more than 10-year experience can suggest where shortcomings in management are and can pave the way for future improvement. Copyright © 2010 by Mutaz B. Habal, MD.
Mahillo B.,Medical Unit |
Carmona M.,Technical Unit |
Alvarez M.,Technical Unit |
Noel L.,World Health Organization |
Matesanz R.,Technical Unit
Transplantation Reviews | Year: 2013
The Global Database on Donation and Transplantation represents the most comprehensive source to date of worldwide data concerning activities in organ donation and transplantation derived from official sources, as well as information on legal and organizational aspects. The objectives are to collect, analyse and disseminate this kind of information of the WHO Member States and to facilitate a network of focal persons in the field of transplantation. They are responsible for providing the legislative and organizational aspects and the annual activity practices through a specific questionnaire. 104 out of the 194 WHO Member States that cover the 90% of the global population contribute to this project.Although we know the numerous limitations and biases as a result of the different interpretations of the questions, based on cultural factors and language, there is no other similar approach to collect information on donation and transplantation practices all over the world. The knowledge of demand for transplantation, availability of deceased and living donor organs and the access to transplantation is essential to monitor global trends in transplantation needs and donor organ availability. Information regarding the existence of regulatory oversight is fundamental to ensure the ethical practice of organ donation and transplantation. © 2013 Elsevier Inc.
Tianyi G.,Medical Unit
Chinese Journal of Traumatology - English Edition | Year: 2014
Skin is the first organ exposed to sulfur mustard (SM). The mechanism of SM-induced cutaneous injury has not been fully clarified so far, which is a major obstacle to the development of effective treatments for SM-induced injury. So far, there is no satisfactory therapy for acute symptoms and long-term complications. This review summarized recent researches on the mechanisms of SM-induced cutaneous injuries and the therapies for acute symptoms and long-term complications. © 2014 Daping hospital and the Research Institute of Surgery of the Third Military Medical University.